UNSPSC 51342705: Interferon alfa-2a

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RRR83SK7. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12447MIG. As of Q4 2014, INTERFERON ALFA-2A remains the US FDA Preferred Term for this commodity. SMILES: NONE.

UNSPSC 51342705 Interferon alfa-2a is a Commodity code that classifies a specific antiviral pharmaceutical product, but recent state and local procurement activity under this code shows minimal alignment with the nominal scope. The two most recent opportunities posted under this code — an Illinois Department of Public Health pharmaceutical warehouse piggyback contract and a Seminole County, Florida purchase of naloxone and drug deactivation systems — involve antibiotics, opioid antagonists, and harm-reduction supplies rather than interferon alfa-2a itself. State and local buyers using this code appear to include public health departments and county health agencies, though the mismatch between the code's specificity and the actual products being procured suggests either tagging inconsistency or that interferon alfa-2a is bundled with broader pharmaceutical supply categories in state and local taxonomy.

Geographic activity under this code spans Florida and Illinois based on recent opportunities, though the sparse posting history and the disconnect between code name and actual procurement content make this code a low-activity segment. The Illinois Department of Public Health awarded a $2.999 million contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC in August 2026 under an Invitation for Bid process for antibiotic products. Seminole County issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. Neither opportunity explicitly solicits interferon alfa-2a, signaling either limited state and local demand for this specific antiviral or systematic coding drift within procurement systems.